drugset / Trial / NCT03029091
An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)
Phase 2
Completed
15 enrolled
Children's Hospital Medical Center, Cincinnati
National Center for Advancing Translational Sciences (NCATS) · collabNational Institute of Allergy and Infectious Diseases (NIAID) · collabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabOffice of Rare Diseases (ORD) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety and effectiveness of Losartan potassium in subjects with eosinophilic esophagitis (EoE) including those with a connective tissue disorder (CTD) and those without a CTD.
Timeline
- Start
- 2017-05-23
- Primary completion
- 2019-07-22
- Completion
- 2019-08-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Losartan | Other / unclassified | 1 mg/kg | — |
| Subject | Losartan | Other / unclassified | 1.4 mg/kg | — |